|
 |
News |
 |
| |
wrote:
ViroPharma Incorporated today announced that it has initiated an open-label, single-dose Phase 2 study to evaluate doses of Cinryze (C1 esterase inhibitor [human)] for treatment of acute angioedema attacks in children less than 12 years of age with hereditary angioedema.
/ permalink
|
|
|
|
Latest Posts
| |
|
|
Latest Articles
| |
|
Home Page